Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience

Fabien Le Bras; Marie Sebert; Charikleia Kelaidi; Thierry Lamy; François Dreyfus; Jacques Delaunay; Anne Banos; Michel Blanc; Norbert Vey; Aline Schmidt; Sorin Visanica; Virginie Eclache; Pascal Turlure; Odile Beyne-Rauzy; Agnès Guerci; Alain Delmer; Stéphane de Botton; Delphine Rea; Pierre Fenaux; Lionel Adès

doi:10.1016/j.leukres.2011.05.034

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience

Fabien Le Bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, François Dreyfus, Jacques Delaunay, Anne Banos, Michel Blanc, Norbert Vey, Aline Schmidt, Sorin Visanica, Virginie Eclache, Pascal Turlure, Odile Beyne-Rauzy, Agnès Guerci, Alain Delmer, Stéphane de Botton, Delphine Rea, Pierre Fenaux, Lionel Adès

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

35 Citations (Scopus)

Résumé

We treated 95 RBC transfusion dependent lower risk MDS with del 5q with Lenalidomide (10 mg/day, 3 weeks/4 weeks). Median age was 70.4, median interval from diagnosis 29 months. IPSS was low in 31% and intermediate-1 in 69% patients. Del 5q was isolated, with 1 additional and >1 additional abnormality in 79%, 14%, and 6% patients, respectively. 62 (65%) patients achieved transfusion independence (TI). The only significant factor predicting TI was baseline platelet count >150. G/L and platelet decrease by at least 50% during the first weeks of treatment (p= 0.001). Grade III-IV neutropenia and thrombocytopenia were seen in 74% and 37.9% of the cases, respectively, and 3 deaths were attributed to cytopenias. Eight (8%) patients developed deep venous thrombosis (DVT). Platelet decrease by less than 50% predicted a higher risk of DVT. Only 6 patients (6.3%) patients progressed to AML, but median follow-up time was short (18 months). We confirm the high rate of TI with Lenalidomide in lower risk MDS with del 5q. Very close patient monitoring for cytopenias and DVT is mandatory, especially during the first weeks of treatment.

langue originale	Anglais
Pages (de - à)	1444-1448
Nombre de pages	5
journal	Leukemia Research
Volume	35
Numéro de publication	11
Les DOIs	https://doi.org/10.1016/j.leukres.2011.05.034
état	Publié - 1 nov. 2011

Accès au document

10.1016/j.leukres.2011.05.034

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Le Bras, F., Sebert, M., Kelaidi, C., Lamy, T., Dreyfus, F., Delaunay, J., Banos, A., Blanc, M., Vey, N., Schmidt, A., Visanica, S., Eclache, V., Turlure, P., Beyne-Rauzy, O., Guerci, A., Delmer, A., de Botton, S., Rea, D., Fenaux, P., & Adès, L. (2011). Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience. Leukemia Research, 35(11), 1444-1448. https://doi.org/10.1016/j.leukres.2011.05.034

@article{950f98d771b14c358ce842e0fa6eb102,

title = "Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience",

abstract = "We treated 95 RBC transfusion dependent lower risk MDS with del 5q with Lenalidomide (10 mg/day, 3 weeks/4 weeks). Median age was 70.4, median interval from diagnosis 29 months. IPSS was low in 31% and intermediate-1 in 69% patients. Del 5q was isolated, with 1 additional and >1 additional abnormality in 79%, 14%, and 6% patients, respectively. 62 (65%) patients achieved transfusion independence (TI). The only significant factor predicting TI was baseline platelet count >150. G/L and platelet decrease by at least 50% during the first weeks of treatment (p= 0.001). Grade III-IV neutropenia and thrombocytopenia were seen in 74% and 37.9% of the cases, respectively, and 3 deaths were attributed to cytopenias. Eight (8%) patients developed deep venous thrombosis (DVT). Platelet decrease by less than 50% predicted a higher risk of DVT. Only 6 patients (6.3%) patients progressed to AML, but median follow-up time was short (18 months). We confirm the high rate of TI with Lenalidomide in lower risk MDS with del 5q. Very close patient monitoring for cytopenias and DVT is mandatory, especially during the first weeks of treatment.",

keywords = "Del 5q syndrome, Lenalidomide, Myelodysplasia",

author = "{Le Bras}, Fabien and Marie Sebert and Charikleia Kelaidi and Thierry Lamy and Fran{\c c}ois Dreyfus and Jacques Delaunay and Anne Banos and Michel Blanc and Norbert Vey and Aline Schmidt and Sorin Visanica and Virginie Eclache and Pascal Turlure and Odile Beyne-Rauzy and Agn{\`e}s Guerci and Alain Delmer and {de Botton}, St{\'e}phane and Delphine Rea and Pierre Fenaux and Lionel Ad{\`e}s",

year = "2011",

month = nov,

day = "1",

doi = "10.1016/j.leukres.2011.05.034",

language = "English",

volume = "35",

pages = "1444--1448",

journal = "Leukemia Research",

issn = "0145-2126",

number = "11",

}

Le Bras, F, Sebert, M, Kelaidi, C, Lamy, T, Dreyfus, F, Delaunay, J, Banos, A, Blanc, M, Vey, N, Schmidt, A, Visanica, S, Eclache, V, Turlure, P, Beyne-Rauzy, O, Guerci, A, Delmer, A, de Botton, S, Rea, D, Fenaux, P & Adès, L 2011, 'Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience', Leukemia Research, VOL. 35, Numéro 11, p. 1444-1448. https://doi.org/10.1016/j.leukres.2011.05.034

TY - JOUR

T1 - Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience

AU - Le Bras, Fabien

AU - Sebert, Marie

AU - Kelaidi, Charikleia

AU - Lamy, Thierry

AU - Dreyfus, François

AU - Delaunay, Jacques

AU - Banos, Anne

AU - Blanc, Michel

AU - Vey, Norbert

AU - Schmidt, Aline

AU - Visanica, Sorin

AU - Eclache, Virginie

AU - Turlure, Pascal

AU - Beyne-Rauzy, Odile

AU - Guerci, Agnès

AU - Delmer, Alain

AU - de Botton, Stéphane

AU - Rea, Delphine

AU - Fenaux, Pierre

AU - Adès, Lionel

PY - 2011/11/1

Y1 - 2011/11/1

N2 - We treated 95 RBC transfusion dependent lower risk MDS with del 5q with Lenalidomide (10 mg/day, 3 weeks/4 weeks). Median age was 70.4, median interval from diagnosis 29 months. IPSS was low in 31% and intermediate-1 in 69% patients. Del 5q was isolated, with 1 additional and >1 additional abnormality in 79%, 14%, and 6% patients, respectively. 62 (65%) patients achieved transfusion independence (TI). The only significant factor predicting TI was baseline platelet count >150. G/L and platelet decrease by at least 50% during the first weeks of treatment (p= 0.001). Grade III-IV neutropenia and thrombocytopenia were seen in 74% and 37.9% of the cases, respectively, and 3 deaths were attributed to cytopenias. Eight (8%) patients developed deep venous thrombosis (DVT). Platelet decrease by less than 50% predicted a higher risk of DVT. Only 6 patients (6.3%) patients progressed to AML, but median follow-up time was short (18 months). We confirm the high rate of TI with Lenalidomide in lower risk MDS with del 5q. Very close patient monitoring for cytopenias and DVT is mandatory, especially during the first weeks of treatment.

AB - We treated 95 RBC transfusion dependent lower risk MDS with del 5q with Lenalidomide (10 mg/day, 3 weeks/4 weeks). Median age was 70.4, median interval from diagnosis 29 months. IPSS was low in 31% and intermediate-1 in 69% patients. Del 5q was isolated, with 1 additional and >1 additional abnormality in 79%, 14%, and 6% patients, respectively. 62 (65%) patients achieved transfusion independence (TI). The only significant factor predicting TI was baseline platelet count >150. G/L and platelet decrease by at least 50% during the first weeks of treatment (p= 0.001). Grade III-IV neutropenia and thrombocytopenia were seen in 74% and 37.9% of the cases, respectively, and 3 deaths were attributed to cytopenias. Eight (8%) patients developed deep venous thrombosis (DVT). Platelet decrease by less than 50% predicted a higher risk of DVT. Only 6 patients (6.3%) patients progressed to AML, but median follow-up time was short (18 months). We confirm the high rate of TI with Lenalidomide in lower risk MDS with del 5q. Very close patient monitoring for cytopenias and DVT is mandatory, especially during the first weeks of treatment.

KW - Del 5q syndrome

KW - Lenalidomide

KW - Myelodysplasia

UR - http://www.scopus.com/inward/record.url?scp=80053956542&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.05.034

DO - 10.1016/j.leukres.2011.05.034

M3 - Article

C2 - 21715006

AN - SCOPUS:80053956542

SN - 0145-2126

VL - 35

SP - 1444

EP - 1448

JO - Leukemia Research

JF - Leukemia Research

IS - 11

ER -